Results

1–10 of 292 results for Diabetic Retinopathy

Benefits and Value of Treatment for Diabetic Macular Edema
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2022
Utilization, Payments, and Effectiveness of Teleophthalmology for Remote Diabetic Eye Screening in the US
Parisa Emami Naeini, MD, MPH
Annual Meeting Talks
2022
Association of Ultra-Widefield Fluorescein Angiography-identified Retinal Nonperfusion With Risk of Diabetic Retinopathy Worsening Over Time
Paolo Antonio S. Silva, MD
Annual Meeting Talks
2022
Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker for the Treatment of Diabetic Macular Edema
Victor Hugo Gonzalez, MD
Updates from the Field
2024
Risk of Sight-Threatening Diabetic Retinopathy with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes
Andrew J. Barkmeier, MD
Updates from the Field
2024
Investigating the Utility of Near-Infrared Reflectance Imaging for Diabetic Retinopathy Screening
Mina M Naguib, MD
Annual Meeting Talks
2022
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases
Matthew Starr, MD
Annual Meeting Talks
2022
Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022